To ask the Secretary of State for Health and Social Care, if he will make it his policy to submit the Sinopharm vaccine to the MHRA and JCVI for consideration as an alternative to currently available vaccines, for those who are unable to receive their first dose of covid-19 vaccine for medical reasons.
The Department does not submit treatments or medicines to the Medicines and Healthcare products Regulatory Agency (MHRA) or the Joint Committee on Vaccination and Immunisation for authorisation. Vaccine developers must submit the relevant clinical trial data and safety information to the regulator for consideration. Any route to approval of new vaccine treatments will be subject to the developer seeking regulatory approval from the MHRA. As with all other COVID-19 vaccines, the MHRA will ensure a thorough and expedited assessment of this medicine’s safety and efficacy before any authorisation.